A Randomized, Active-controlled, Open Label, 2-treatment Arm, and Multicenter Study Comparing the Efficacy and Safety of Insulin Glargine/Lixisenatide Combination to Lixisenatide on Top of OADs in Japanese Patients With Type 2 DM With an Extension Period
收藏DataCite Commons2025-03-04 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00008817/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
Primary Objective:
To compare LixiLan to lixisenatide in glycated hemoglobin (HbA1c) change from baseline to
Week 26 in patients with type 2 diabetes mellitus.
Secondary Objective:
To compare the overall efficacy and safety of LixiLan to lixisenatide (with or without OADs)
over a 52 week treatment period in patients with type 2 diabetes mellitus.
提供机构：
Vivli
创建时间：
2023-02-27
